ClinicalTrials.gg
CompletedNCT00002446Updated Jun 24, 2005

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

A Phase 3 interventional study of Posaconazole and Fluconazole in Candidiasis, Oral and HIV Infections, sponsored by Schering-Plough. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Schering-Plough (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Candidiasis, Oral with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Candidiasis, Oral · United States.

Enrollment
3rd of 13
300 · median 70
Started
1998
the only one that year
Phase 3
2 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
2 of 26
Schering-Plough

Among the 26 studies in Candidiasis, Oral with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 1998, is one of 2 in phase 3, and was the 1st registered.

Candidiasis, Oral

48 studies on the registry are indexed under Candidiasis, Oral; 6 are open to participants now.

Browse Candidiasis, Oral studies →

Open to participants now

2 of the 26 studies in Candidiasis, Oral with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Candidiasis, Oral studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Candidiasis, Oral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.

Read the detailed description

Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.

03

Conditions studied

  • Candidiasis, Oral
  • HIV Infections

Keywords

  • AIDS-Related Opportunistic Infections
  • Fluconazole
  • Administration, Oral
  • Antifungal Agents
  • Candidiasis, Oral
  • Pharyngeal Diseases
  • posaconazole
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

You may be eligible for this study if you:

  • Are at least 18 years old.
  • Are -positive.
  • Have thrush (oropharyngeal candidiasis).
  • Agree to practice sexual abstinence or use effective barrier methods of (e.g., condoms).
  • Are able to take study medication and return for clinic visits during the study.
  • Are expected to live for at least 2 months.

Exclusion criteria

Exclusion Criteria

You will not be eligible for this study if you:

  • Have received protease inhibitors for the first time within 30 days prior to study entry.
  • Have received certain medications.
  • Have certain other types of fungal infections.
  • Have certain types of cancer.
  • Have received SCH 56592 within 3 months prior to study entry.
  • Are pregnant or breast-feeding.
  • Cannot take medications by mouth.
  • Are allergic to azole drugs.
  • Have certain medical conditions.
  • Have been in this study before.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double
Enrollment
300 participants

Interventions

06

Study locations

18 sites
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • ViRx Inc
    San Francisco, California 94109, United States
  • Kaiser Foundation Hospital
    San Francisco, California 94118, United States
  • Infectious Disease and AIDS Clinic
    Denver, Colorado 80204, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • Boulevard Comprehensive Care Ctr
    Jacksonville, Florida 32209, United States
  • Miami Veterans Administration Med Ctr
    Miami, Florida 33125, United States
  • TRIAD Health Practice
    Chicago, Illinois 60657, United States
  • Community Hosp Indianapolis
    Indianapolis, Indiana 46219, United States
  • Wayne State Univ / Harper Hosp
    Detroit, Michigan 48201, United States
  • UMDNJ - New Jersey Med School / Cooper Hosp
    Camden, New Jersey 08103, United States
  • Jersey City Med Ctr
    Jersey City, New Jersey 07304, United States
  • SUNY / Health Science Ctr at Brooklyn
    Brooklyn, New York 11203, United States
  • Univ of Pennsylvania School of Dental Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Med Univ of South Carolina
    Charleston, South Carolina 29425, United States
  • Amelia Ct Clinic
    Dallas, Texas 75235, United States
  • Univ of Texas Health Sciences Ctr
    San Antonio, Texas 78284, United States
  • Queen Elizabeth Hosp Respiratory Unit
    St Michael, Barbados
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002446
Lead sponsor
Schering-Plough
First posted
Aug 31, 2001
Start date
Aug 1998
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion